Meeting
2022 ASCO Genitourinary Cancers Symposium
A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer.
Authors
David James VanderWeele
Northwestern Unis, Chicago, IL
David James VanderWeele , Masha Kocherginsky , Sabah Munir , Brenda K. Martone , Alicia K. Morgans , Walter Michael Stadler , Sarki Abdulkadir , Maha H. A. Hussain
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04033432
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 84)
DOI
10.1200/JCO.2022.40.6_suppl.084
Abstract #
84
Poster Bd #
D11
Abstract Disclosures
Similar Posters
Poster
2017 Genitourinary Cancers Symposium
A phase II trial of zoptarelin doxorubicin in castration- and taxane-resistant prostate cancer.
First Author: Steven Yu
Poster
2022 ASCO Genitourinary Cancers Symposium
KEYNOTE-365 cohorts E and F: Phase 1b/2 study of pembrolizumab + lenvatinib combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).
First Author: Gero Kramer
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naive metastatic castration-resistant prostate cancer (mCRPC).
First Author: Scott T. Tagawa
Poster
2016 ASCO Annual Meeting
A phase I/II trial of enzalutamide plus the glucocorticoid receptor antagonist mifepristone for patients with metastatic castration resistant prostate cancer (mCRPC).
First Author: Russell Zelig Szmulewitz